This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.36, moving -0.75% from the previous trading session.
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
by Zacks Equity Research
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $33.80, marking a +0.6% move from the previous day.
Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
by Zacks Equity Research
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DNL
Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
by Zacks Equity Research
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.
GSK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
Stock Market News for Apr 27, 2023
by Zacks Equity Research
Wall Street closed mixed on Wednesday.
GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook
by Zacks Equity Research
Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.
GSK (GSK) Tops Q1 Earnings Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $36.91, moving +0.71% from the previous trading session.
Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.93, marking a +0.41% move from the previous day.
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
by Zacks Equity Research
Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
by Zacks Equity Research
Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $38.32, moving +1.62% from the previous trading session.
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $37.87, marking a -0.34% move from the previous day.